EPRX Archives - BioTuesdays

Markets

Raymond James ups Eupraxia PT on new osteoarthritis data

Raymond James raised its price target for Eupraxia Pharmaceuticals (TSX:EPRX) to $17 (Canadian) from $11, maintaining a “strong buy” rating, after the company reported positive Phase 2b data with EP-104IAR for pain...

June 27, 2023

Markets

RC ups PT; RJ reiterates ‘strong buy’, for Eupraxia on Phase 2b osteoarthritis data

Research Capital raised its price target for Eupraxia Pharmaceuticals (TSX:EPRX) to $25 (Canadian) from $10.30 and maintained a “speculative buy” rating after the company reported positive results from its Phase 2b...

June 26, 2023

Markets

RJ ups Eupraxia to strong buy ahead of Phase 2 OA data

Raymond James upgraded Eupraxia Pharmaceuticals (TSX:EPRX) to “strong buy” from “outperform” and maintained its price target of $11 (Canadian). The stock was quoted at $6.99, up 15 cents at midday on May 18. Pointing to...

May 18, 2023

Markets

Research Capital starts Eupraxia at speculative buy; PT $10.30 (Canadian)

Research Capital launched coverage of Eupraxia Pharmaceuticals (TSX:EPRX) with a “speculative buy” rating and price target of $10.30 (Canadian). The stock closed at $3.69 on Jan. 6. Eupraxia’s lead product, EP...

January 9, 2023

Markets

Raymond James ups Eupraxia PT to $9 (Canadian) on Phase 2 EoE trial

Raymond James raised its price target for Eupraxia Pharmaceuticals (TSXV:EPRX) to $9 (Canadian) from $7 and reiterated its “outperform” rating after the company initiated a Phase 2 clinical trial in eosinophilic...

October 31, 2022

Feature

Eupraxia Pharmaceutical’s novel release technology aims to improve lives of knee OA sufferers

Eupraxia Pharmaceuticals (TSX:EPRX) is developing a unique diffusion-based polymer-particle technology initially to provide knee osteoarthritis (OA) patients with an injection in the knee for an extended release of drug...

July 26, 2022

Developments

Eupraxia Pharma receives emerging life sciences award for 2022 in B.C.

Eupraxia Pharmaceuticals (TSX:EPRX) received the Emerging Life Sciences Company Award of the year from Life Sciences British Columbia. In a statement, Dr. James Helliwell, CEO of Eupraxia, said that following a...

July 9, 2022

Markets

Raymond James resumes coverage of Eupraxia at OP; PT $7 (Canadian)

Raymond James resumed coverage of Eupraxia Pharmaceuticals (TSX:EPRX) with an “outperform” rating and $7 (Canadian) price target. The stock closed at $1.36 on June 8. Eupraxia’s lead clinical candidate, EP-104IAR...

June 9, 2022

Markets

Raymond James starts Eupraxia Pharma at OP; PT $13 (Canadian)

Raymond James initiated coverage of Eupraxia Pharmaceuticals (TSX:EPRX) with an “outperform” rating and a $13 price target. The stock closed at $6.21 on April 12. Eupraxia aims to address the growing burden of...

April 13, 2021

Tag - EPRX

Raymond James ups Eupraxia PT on new osteoarthritis data

RC ups PT; RJ reiterates ‘strong buy’, for Eupraxia on Phase 2b osteoarthritis data

RJ ups Eupraxia to strong buy ahead of Phase 2 OA data

Research Capital starts Eupraxia at speculative buy; PT $10.30 (Canadian)

Raymond James ups Eupraxia PT to $9 (Canadian) on Phase 2 EoE trial

Eupraxia Pharmaceutical’s novel release technology aims to improve lives of knee OA sufferers

Eupraxia Pharma receives emerging life sciences award for 2022 in B.C.

Raymond James resumes coverage of Eupraxia at OP; PT $7 (Canadian)

Raymond James starts Eupraxia Pharma at OP; PT $13 (Canadian)

General

More